SLNO News & Analysis

Soleno Therapeutics (SLNO) Stock Rating Cut Following Acquisition Deal

Stifel reduced the stock rating for Soleno Therapeutics (SLNO) amid news of its acquisition deal, although specific financial details of the deal were not disclosed. The adjustment indicates a cautious outlook on SLNO's performance following the announcement. Acquisition deals often impact stock values due to shifts in operational focus and investor sentiment. How this will affect the future market performance of Soleno remains to be seen.